Arrakis Therapeutics reduces headcount by 20%

Arrakis Therapeutics has prioritized its pipeline and reduced its headcount by about 20% this week, the biotech’s CEO said in a statement to Endpoints News.

“We conducted a thorough review of our pipeline and have prioritized programs and activities that we’re most excited about and provide us with the clearest…
Click here to view original post

Click Here to Publish/Feature Your Company or Product News with Biotech Networks